Published date:
24/01/2023
Summary:
– Amber-UI presents a unique and significant opportunity to treat urge and mixed urinary incontinence by targeting the pudendal nerve
– Amber-UI can sense, interpret, adapt and respond to individual patient signals to restore normal bladder function
– Ground-breaking clinical study (AURA-2) will evaluate safety and pilot efficacy of Amber-UI to treat urge and mixed urinary incontinence
– Early data confirm feasibility of surgical procedure and therapy, with full read out expected later in 2023
London, UK and Antwerp, Belgium. 24th January 2023 – Amber Therapeutics (‘Amber’ or the ‘Company’), a University of Oxford spinout developing next-generation, intelligent bioelectrical therapies to transform clinical outcomes in patients with functional disorders of the peripheral nervous system, announces that the first participants have been implanted with Amber-UI, the Company’s proprietary therapy for urge and mixed urinary incontinence (UI).
